HL-60 is a suspension cell line established from peripheral blood via leukapheresis from a patient with acute promyelocytic leukemia. These cells are promyelocytes but depending on culture conditions, HL-60 can differentiate into different lineages of mature myeloid cells; this makes it a useful model for immune response studies.

The HL-60 cell line is a human leukemia cell line that has been used for laboratory research on blood cell formation and physiology. HL-60 proliferates continuously in suspension culture in nutrient and antibiotic chemicals.

Mar 11, 2025 · HL-60 cells are a critical model for studying human myeloid cell behavior, particularly differentiation and immune responses. Derived from a patient with acute promyelocytic leukemia, these cells help researchers investigate innate immunity processes, including chemotaxis and collective movement.

The HL60 cell line was established in 1977 from a patient with acute myeloid leukaemia. The cells largely resemble promyelocytes but can be induced to differentiate terminally in vitro. Some reagents cause HL60 cells to differentiate to granulocyte-like cells, others to monocyte/macrophage-like cells.

Induction of differentiation in a human promyelocytic leukemic cell line (HL-60). Production of granule proteins.

Jan 12, 2021 · Here we provide evidence of swarming and chemotaxis in differentiated HL-60 neutrophil-like cells (dHL-60) using precise microfluidic assays.

The HL-60 cell line is a promyelocytic cell line derived from human leukemia (Collins, Gallo, & Gallagher, 1977). The cells are premyelocytes, but can be induced in vitro to differentiate into different lineages of mature myeloid cells depending on the reagents used for induction (Collins, Ruscetti, Gallagher, & Gallo, 1978). If dimethyl ...

HL-60 is an immortal human leukemia cell line. It is widely used to study cancer biology and to explore the efficacy of anti-cancer drugs. Moreover, it can also be used to understand different cellular and molecular mechanisms involved in leukemic cell proliferation and differentiation.

The HL60 cell line was established in 1977 from a patient with acute myeloid leukaemia. The cells largely resemble promyelocytes but can be induced to differentiate terminally in vitro. Some reagents cause HL60 cells to differentiate to granulocyte-like cells, others to monocyte/macrophage-like cells.

HL-60/MX1 cells display atypical multidrug resistance (MDR), altered topoisomerase II catalytic activity and reduced levels of topoisomerase II alpha and beta proteins. HL-60/MX1 cells are cross resistant to etoposide, teniposide, bisantrene.